IO Biotech will discuss Phase 3 trial results for its cancer vaccine, Cylembio, on August 11, 2025.
Quiver AI Summary
IO Biotech announced that it will hold a conference call and webcast on August 11, 2025, at 8:30 AM ET to share the topline results from its pivotal Phase 3 trial of its cancer vaccine Cylembio, which is being evaluated as a first-line treatment for advanced melanoma in combination with pembrolizumab. The company invites participants to join the live event, and a replay will be available on its website afterward. IO Biotech focuses on developing innovative immune-modulatory cancer vaccines through its T-win® platform, and its lead candidate, Cylembio, has shown promising results in earlier trials and has received Breakthrough Therapy Designation from the FDA for treating advanced melanoma. The company is based in Copenhagen with a U.S. headquarters in New York.
Potential Positives
- Announcement of a conference call and webcast to disclose pivotal Phase 3 trial results demonstrates transparency and communication with investors and stakeholders.
- The positive Phase 1/2 trial data previously reported has led to Breakthrough Therapy Designation from the FDA for their lead product Cylembio, indicating strong potential for the company’s development pipeline.
- The investigational product Cylembio represents an innovative approach to cancer treatment, which may enhance the company's reputation in the biopharmaceutical industry.
Potential Negatives
- The press release mentions that the company is disclosing topline results of a pivotal Phase 3 trial, which implies that the trial is critical for the future of the company's lead candidate, Cylembio. If the results are unfavorable, it could significantly impact investor confidence and the company's market position.
- IO Biotech is still in the clinical stage, suggesting that it has not yet achieved commercial success, which may raise concerns about its financial stability and long-term viability.
- The reliance on a single investigational product (Cylembio) for interim communication indicates a high level of risk associated with the company's pipeline, potentially making investors wary of the company's prospects.
FAQ
When is IO Biotech's conference call to discuss trial results?
IO Biotech's conference call is scheduled for Monday, August 11, 2025, at 8:30 AM ET.
How can I access the webcast of the conference call?
You can access the live webcast through the link provided in the press release or register for the teleconference.
What is the focus of the Phase 3 trial for Cylembio?
The Phase 3 trial focuses on evaluating Cylembio as a first-line treatment for unresectable or metastatic melanoma.
What is Cylembio and how does it work?
Cylembio is an immune-modulatory cancer vaccine designed to activate T cells to target tumor and immune-suppressive cells in the tumor microenvironment.
Where is IO Biotech headquartered?
IO Biotech is headquartered in Copenhagen, Denmark, with a US office in New York, New York.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IOBT Insider Trading Activity
$IOBT insiders have traded $IOBT stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IOBT stock by insiders over the last 6 months:
- HEIDI HUNTER purchased 15,000 shares for an estimated $20,884
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IOBT Hedge Fund Activity
We have seen 5 institutional investors add shares of $IOBT stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 224,949 shares (-83.2%) from their portfolio in Q1 2025, for an estimated $245,194
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 99,000 shares (-56.9%) from their portfolio in Q1 2025, for an estimated $107,910
- MORGAN STANLEY removed 69,714 shares (-8.1%) from their portfolio in Q1 2025, for an estimated $75,988
- DAUNTLESS INVESTMENT GROUP, LLC removed 66,200 shares (-8.9%) from their portfolio in Q1 2025, for an estimated $72,158
- ROYAL BANK OF CANADA removed 60,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $65,400
- LANDSCAPE CAPITAL MANAGEMENT, L.L.C. removed 41,962 shares (-9.5%) from their portfolio in Q1 2025, for an estimated $45,738
- UBS GROUP AG removed 34,675 shares (-73.7%) from their portfolio in Q1 2025, for an estimated $37,795
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IOBT Analyst Ratings
Wall Street analysts have issued reports on $IOBT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/01/2025
To track analyst ratings and price targets for $IOBT, check out Quiver Quantitative's $IOBT forecast page.
Full Release
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.
Webcast and Conference Call Information
The IO Biotech management team will host a webcast/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to participate may access the live webcast here or register in advance for the teleconference here . A replay of the webcast will be available on the IO Biotech website following the live event.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com . Follow us on our social media channels on LinkedIn and X ( @IOBiotech ).
Contacts:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
[email protected]
Media
Julie Funesti
Edelman
917-498-1967
[email protected]
